PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release
150
PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release
150
PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions
| Official URL: http://hl7.eu/fhir/ig/pcsp/ValueSet/vs-riskfactor-eu-pcsp | Version: 1.0.0 | |||
| Active as of 2026-01-16 | Computable Name: RiskFactor | |||
Risk Factors used by the PCSP algorithm
References
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp version 📦1.0.0
Expansion performed internally based on codesystem Risk Factors v1.0.0 (CodeSystem)
This value set contains 112 concepts
| System | Code | Display (en) | Definition | JSON | XML |
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 1.1 | RT to a vol exposing the thyroid gland | RT to a vol exposing the thyroid gland | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 1.2 | TBI | TBI | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 1.3 | MIBG therapy (I-131 MIBG therapy) | MIBG therapy (I-131 MIBG therapy) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 2.1 | RT >= 10 Gy to a vol exposing the breasts | RT >= 10 Gy to a vol exposing the breasts | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 2.2 | OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age | OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 3.1 | RT >= 35 Gy to a vol exposing the heart | RT >= 35 Gy to a vol exposing the heart | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 3.2 | Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2 | Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2 | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 3.3 | RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2 | RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2 | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 4.1 | Alkylating agents | Alkylating agents | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 4.2 | RT to a vol exposing the testes | RT to a vol exposing the testes | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 4.3 | Including TBI | Including TBI | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 5.1 | RT >=12 Gy to a vol exposing the testicles | RT >=12 Gy to a vol exposing the testicles | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 6.3 | Surgery to the spinal cord, sympathetic nerves or pelvis | Surgery to the spinal cord, sympathetic nerves or pelvis | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 6.4 | Hypogonadal | Hypogonadal | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 7.2 | RT to a vol exposing the ovaries | RT to a vol exposing the ovaries | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 8.1 | RT >= 30 Gy to a vol exposing the head or the brain | RT >= 30 Gy to a vol exposing the head or the brain | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 8.2 | Cisplatin (with or without carboplatin > 1500 mg/m2) | Cisplatin (with or without carboplatin > 1500 mg/m2) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 9.1 | RT to a vol exposing the pancreas | RT to a vol exposing the pancreas | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 10.2 | HSCT | HSCT | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 11.1 | RT to a volume exposing the hypothalamus or pituatary gland | RT to a volume exposing the hypothalamus or pituatary gland | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 11.3 | Hypothalamic or pituitary tumour | Hypothalamic or pituitary tumour | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 11.4 | Neurosurgery of the hypothalamus or pituitary gland | Neurosurgery of the hypothalamus or pituitary gland | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 12.1 | RT to a vol exposing the kidneys, heart and associated large vessels | RT to a vol exposing the kidneys, heart and associated large vessels | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 12.3 | Nephrectomy | Nephrectomy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 12.4 | Ifosfamide | Ifosfamide | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 12.5 | Platinium based chemotherapy | Platinium based chemotherapy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 12.6 | Nitrosureas | Nitrosureas | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 12.7 | Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously) | Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 13.1 | Cranial and/or spinal RT | Cranial and/or spinal RT | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 13.3 | Methotrexate | Methotrexate | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 13.4 | Gonadal failure | Gonadal failure | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 13.5 | Growth hormone deficiency | Growth hormone deficiency | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 13.6 | Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment | Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 13.7 | HSCT, especially with an history of GVHD | HSCT, especially with an history of GVHD | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 14.3 | High dose RT | High dose RT | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 15.1 | Radiotherapy to a vol exposing the HP region >= 30 Gy | Radiotherapy to a vol exposing the HP region >= 30 Gy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 15.2 | Surgery near or within the HP region | Surgery near or within the HP region | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 15.3 | CNS tumours near or within the HP region | CNS tumours near or within the HP region | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 16.1 | Radiotherapy to a vol exposing the HP region< 30 Gy | Radiotherapy to a vol exposing the HP region< 30 Gy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 16.2 | Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD) | Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 17.1 | Radiotherapy to a vol exposing the HP region | Radiotherapy to a vol exposing the HP region | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 17.5 | hydrocephalus or cerebrospinal fluid shunt | hydrocephalus or cerebrospinal fluid shunt | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 19.3 | Radioiodine therapy (I-131 ablation therapy) | Radioiodine therapy (I-131 ablation therapy) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 19.5 | Allogenic HSCT | Allogenic HSCT | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 19.6 | Total thyroidectomy | Total thyroidectomy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 20.1 | RT to a vol exposing the head, brain or neck | RT to a vol exposing the head, brain or neck | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 21.1 | History of a central nervous system tumor | History of a central nervous system tumor | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 21.2 | RT to a vol exposing the brain ANY DOSE | RT to a vol exposing the brain ANY DOSE | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 21.4 | Brain surgery | Brain surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 21.5 | High dose cytarabine IV (intravenous) | High dose cytarabine IV (intravenous) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 21.6 | High dose MTX IV | High dose MTX IV | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 21.7 | Any Chemotherapy IT (intrathecal) | Any Chemotherapy IT (intrathecal) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 22.1 | Vinca-Alkaloids | Vinca-Alkaloids | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 22.2 | Cisplatin or carboplatin | Cisplatin or carboplatin | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 23.1 | RT to a vol exposing the lens | RT to a vol exposing the lens | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 24.1 | RT to a vol exposing the eye and orbit | RT to a vol exposing the eye and orbit | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 25.1 | RT to a vol exposing the craniofacial area, especially after high doses and at a young age | RT to a vol exposing the craniofacial area, especially after high doses and at a young age | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 25.3 | Surgery to the face, especially at a young age | Surgery to the face, especially at a young age | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 26.1 | Surgery of the spine | Surgery of the spine | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 26.2 | Surgery of the chest (Does not include CVC pose) | Surgery of the chest (Does not include CVC pose) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 26.3 | RT to a vol exposing the spine | RT to a vol exposing the spine | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 26.4 | Spinal or paraspinal malignancies | Spinal or paraspinal malignancies | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 27.1 | Cyclophosphamide | Cyclophosphamide | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 27.3 | RT to a vol exposing the bladder | RT to a vol exposing the bladder | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 27.5 | Cystectomy | Cystectomy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 27.6 | Hysterectomy | Hysterectomy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 27.7 | Pelvic surgery | Pelvic surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 27.8 | Spinal cord surgery | Spinal cord surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 28.1 | RT to a vol exposing the uterus only female | RT to a vol exposing the uterus only female | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 29.1 | RT to a vol exposing the oral cavity or salivary glands | RT to a vol exposing the oral cavity or salivary glands | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 29.4 | Chemotherapy | Chemotherapy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 30.1 | RT to a vol exposing the gastro-intestinal tract | RT to a vol exposing the gastro-intestinal tract | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 30.3 | Oesophageal surgery | Oesophageal surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 30.4 | Abdominal surgery | Abdominal surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 30.5 | With a history of chronic GVHD | With a history of chronic GVHD | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 31.1 | Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2 | Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2 | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 32.1 | RT to a vol exposing the lungs | RT to a vol exposing the lungs | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 32.3 | Bleomycin | Bleomycin | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 32.4 | Busulfan | Busulfan | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 32.5 | BCNU Carmustine | BCNU Carmustine | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 32.6 | CCNU Lomustine | CCNU Lomustine | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 32.7 | Thoracic surgery | Thoracic surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 33.1 | Cisplatin Any dose | Cisplatin Any dose | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 33.2 | Ifosfamide Any dose | Ifosfamide Any dose | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 33.3 | Carboplatin Any dose | Carboplatin Any dose | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.1 | RT to a volume exposing the liver | RT to a volume exposing the liver | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.10 | Chronic GVHD | Chronic GVHD | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.11 | Liver surgery | Liver surgery | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.3 | HSCT (irrespective of GVHD) | HSCT (irrespective of GVHD) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.5 | Mercaptopurine Thioguanine | Mercaptopurine Thioguanine | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.6 | Dactinomycin | Dactinomycin | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.8 | Chronic viral hepatitis | Chronic viral hepatitis | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 34.9 | Sinusoidal obstruction syndrome | Sinusoidal obstruction syndrome | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 35.1 | HSCT (irrespective of GVHD) | HSCT (irrespective of GVHD) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 35.2 | Multiple red blood cell transfusions | Multiple red blood cell transfusions | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 36.1 | Splenectomy | Splenectomy | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 36.2 | RT >= 10 Gy to a vol exposing the spleen | RT >= 10 Gy to a vol exposing the spleen | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 36.3 | Allogenic HSCT (with or without TBI) | Allogenic HSCT (with or without TBI) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 36.4 | Autologus HSCT conditioned with TBI | Autologus HSCT conditioned with TBI | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 37.1 | Hereditary cancer sd | Hereditary cancer sd | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 38.1 | Any RT including TBI (predominantly in the RT field) | Any RT including TBI (predominantly in the RT field) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 38.2 | HSCT Especially with a history of skin GvHD | HSCT Especially with a history of skin GvHD | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 39.1 | RT to a vol exposing the colon and rectum | RT to a vol exposing the colon and rectum | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 40.1 | RT to a vol exposing the oral cavity | RT to a vol exposing the oral cavity | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 41.2 | Anthracyclines and/or Mitoxantrone | Anthracyclines and/or Mitoxantrone | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 41.3 | Epipodophyllotoxins or autologous | Epipodophyllotoxins or autologous | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 41.4 | Autologous haematopoietic stem cell transplant | Autologous haematopoietic stem cell transplant | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 42.1 | Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis) | Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis) | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 45.1 | RT to a vol exposing the head or brain | RT to a vol exposing the head or brain | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 46.1 | RT between 15 and 35 Gy to a vol exposing the heart | RT between 15 and 35 Gy to a vol exposing the heart | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 46.2 | Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2 | Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2 | ||
http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp | 47.1 | RT to a vol exposing the kidney or urinary tract | RT to a vol exposing the kidney or urinary tract |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |
IG © 2021+ PanCareSurPass Project. Package hl7.eu.fhir.pcsp#1.0.0 based on FHIR 4.0.1. Generated 2026-01-16
Links: Table of Contents |
QA Report
The PanCareSurPass Research and Innovation Action has received funding from the European Union's Horizon 2020
research and innovation programme under grant agreement No. 899999.
